22 peptides tracked
Australia's
Independent
Peptide Register
No vendors. No affiliates. Just data.
Fig. 01
Regulatory Status · May 2026
Retatrutide2
GHK-Cu10
Semaglutide12
Tirzepatide8
BPC-15718
CJC-129515
22
Peptides tracked
40
Prescription providers
52
Observed suppliers
1
Prohibited (S9)
01Intelligence
Peptide Status
TGA scheduling, enforcement trends, and access pathways for each peptide. Updated September 2026.
Editorial position: We recommend accessing peptides through an AHPRA-registered medical practitioner and TGA-licensed compounding pharmacy. This ensures clinical oversight, pharmaceutical-grade compounding, and legal compliance.
Retatrutide
Triple Agonist (GLP-1/GIP/Glucagon)
GHK-Cu
Copper Peptide
Semaglutide
GLP-1 Agonist
Tirzepatide
GLP-1/GIP Agonist
BPC-157
Tissue Repair
CJC-1295
Growth Hormone Secretagogue
Ipamorelin
Growth Hormone Secretagogue
TB-500
Tissue Repair
Melanotan II
Melanocortin Agonist
PT-141 (Bremelanotide)
Melanocortin Agonist
MOTS-c
Mitochondrial Peptide
Thymosin Alpha-1
Immune Modulator
KPV
Anti-inflammatory Peptide
Epithalon
Telomerase Activator
Gonadorelin
Hormonal Support
Dihexa
Cognitive Enhancement
02News
Regulatory Feed
Latest scheduling changes, enforcement actions, and market developments across all tracked peptides.
HeadlineSourceDate
Redox imbalance and mitochondrial dysfunction in gestational diabetes mellitus: Implications for maternal health, placental function, and offspring metabolic programmingSS-31 (Elamipretide)
Free Radic Biol Med1 Sept 2026Composition and Labelling Accuracy of Products Sold as Retatrutide in AustraliaRetatrutide
Drug Alcohol Rev1 Sept 2026Microvascular dysfunction and neurovascular signalling impairment in diabetic silent myocardial ischemiaSS-31 (Elamipretide)
Microvasc Res1 Sept 2026Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.Semaglutide
Annals of internal medicine1 Sept 2026In adults with early uncontrolled T2D, tirzepatide vs. intensified conventional care reduced HbA1c levels and weight at 2 y.Tirzepatide
Annals of internal medicine1 Sept 2026Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST-T1D Extension Study.Semaglutide
Diabetes, obesity & metabolism31 Aug 2026Comment on "Effect of Semaglutide with Metformin for Weight Loss and Fertility in Polycystic Ovary Syndrome (PCOS) Patients with Obesity: A Pilot Prospective Study".Semaglutide
Clinical nutrition ESPEN31 Aug 2026Reply - Letter to the Editor: Comment on "Effect of Semaglutide with Metformin for Weight Loss and Fertility in Polycystic Ovary Syndrome (PCOS) Patients with Obesity: A Pilot Prospective Study.Semaglutide
Clinical nutrition ESPEN31 Aug 2026Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA.Tirzepatide
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine31 Aug 2026Tirzepatide non-response with subsequent semaglutide response in class 2 obesity.Tirzepatide
JCEM case reports31 Aug 2026Unilateral Graves' Disease Developing During Treatment With Tirzepatide in a Patient With Diabetes: A Case Report.Tirzepatide
Case reports in endocrinology30 Aug 2026Efficient Expression of Small Molecule Bioactive Peptides in Bacillus licheniformisBPC-157
Appl Biochem Biotechnol29 Aug 2026Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysisSemaglutide
International Journal of Obesity29 Aug 2026Semaglutide in Japanese participants with metabolic dysfunction-associated steatohepatitis: a subgroup analysis of the ESSENCE trialSemaglutide
Journal of Gastroenterology28 Aug 2026Effects of Semaglutide versus Bariatric Surgery on Noninvasive Markers of Hepatic Steatosis and Fibrosis in Obesity with MASLDSemaglutide
Journal of Clinical Endocrinology & Metabolism27 Aug 2026Transcriptomic Changes Elicited by Semaglutide in Human Ventricular Tissue Support Cell Survival and Lipid MetabolismSemaglutide
Circulation: Heart Failure27 Aug 2026Data and Temporal Risk Concerns of Semaglutide and NAIONSemaglutide
JAMA Ophthalmology27 Aug 2026Data and Temporal Risk Concerns of Semaglutide and NAION—ReplySemaglutide
JAMA Ophthalmology27 Aug 2026Tirzepatide as a possible trigger of bullous pemphigoid: a case reportTirzepatide
Journal der Deutschen Dermatologischen Gesellschaft27 Aug 2026GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry trial posted on ClinicalTrials.govTirzepatide
ClinicalTrials.gov26 Aug 2026Regulatory Notice
For informational purposes only. TGA scheduling may change without notice. All Schedule 4 peptides require a valid prescription from a registered Australian medical practitioner. This site does not sell, supply, or facilitate access to therapeutic goods. Data compiled from TGA SUSMP, public provider directories, and publicly available review platforms.